Frovatriptan succinate hydrate
Cat. No.：YN321673
| 产品名称: | Frovatriptan succinate hydrate |
| CAS No.: | 158930-17-7 |
| Chemical Name: | butanedioic acid, compd. with (R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide, hydrate (1:1:1) |
| Synonyms: | Frovatriptan succinate [USAN];Frova;butanedioic acid,(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide,hydrate;Frovatriptan;FROVATRIPTAN SUCCINATE MONOHYDRATE;(+)-(R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide butanedio |
| 分子量: | 379.41 |
| 分子式: | C₁₈H₂₅N₃O₆ |
| SMILES: | O=C(O)CCC(O)=O.O=C(C1=CC2=C(NC3=C2C[C@H](NC)CC3)C=C1)N.O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) 是一种强效，高亲和力，选择性和具有口服活性的5-HT1B(pK50为 8.2) 和5-HT1D受体激动剂，选择性是 5-HT1A，5-HT1F和 5-HT7的 10 倍以上，是其他 5-HT，多巴胺，组胺 H1和 α1-肾上腺素受体的 1000 倍以上。Frovatriptan succinate hydrate 可用于偏头痛的研究。 |
| IC50和靶点: | [{name:"5-HT1B Receptor:8.2 (pEC50)'}, '5-HT1D Receptor'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Brown, A.M., Parsons, A.A., Raval, P., et al.SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptorsBr. J. Pharmacol.119(Suppl 1),110P(1996)
Comer, M.B.Pharmacology of the selective 5-HT1B/1D agonist frovatriptanHeadache42(Suppl 2),S47-S53(2002)
Parsons, A.A., Raval, P., Smith, S., et al.Effects of the novel high-affinity 5-HT1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteriesJ. Cardiovasc. Pharmacol.32(2),220-224(1998)
Parsons, A.A., Parker, S.G., Raval, P., et al.Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist, SB 209509 (VML251), and sumatriptan in dogsJ. Cardiovasc. Pharmacol.30(1),136-141(1997)
